Kamiya M, Carter H, Espindola MS, Doyle TJ, Lee JS, Merriam LT et al (2024) Immune mechanisms in fibrotic interstitial lung disease. Cell 11 luglio 187(14):3506–3530
Rodriguez K, Ashby CL, Varela VR, Sharma A (2022) High-resolution computed tomography of fibrotic interstitial lung disease. Semin Respir Crit Care Med dicembre 43(6):764–779
Drimus JC, Duma RC, Trăilă D, Mogoșan CD, Manolescu DL, Fira-Mladinescu O (2025) high-resolution CT findings in interstitial lung disease associated with connective tissue diseases: Differentiating patterns for clinical practice—a systematic review with meta-analysis. J Clin Med gennaio 14(17):6164
Ley S, Ley-Zaporozhan J (2020) Novelties in imaging in pulmonary fibrosis and nodules. A narrative review. Pulmonol 1 gennaio 26(1):39–44
Kewalramani N, Machahua C, Poletti V, Cadranel J, Wells AU, Funke-Chambour M Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges. ERJ Open Research [Internet]. 21 giugno 2022 [citato 27 novembre 2025]; Disponibile su: https://publications.ersnet.org/content/erjor/8/2/00115-2022
Castelli G, Cocconcelli E, Grimaudo G, Di Leo I, Bellani S, Fiorentù G et al (2025) Interstitial lung diseases and lung cancer: A review on similarities, common pathogenesis and therapeutic approach. J Pers Med 15(5):213
Salvatore MM, Liu Y, Peng B, Hsu HY, Saqi A, Tsai WY et al (2024) Comparison of lung cancer occurring in fibrotic versus non-fibrotic lung on chest CT. J Transl Med 22(1):67
Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M et al (2018) Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 27(150):180076
Lee JK, Chung C, Kim J, Cho HS, Kim HC (2023) Clinical impact of weight loss on mortality in patients with idiopathic pulmonary fibrosis: a retrospective cohort study. Sci Rep 8 aprile 13(1):5774
Drakopanagiotakis F, Krauss E, Michailidou I, Drosos V, Anevlavis S, Günther A et al (2024) Lung cancer and interstitial lung diseases. Cancers (Basel) 13 agosto 16(16):2837
Frank AJ, Dagogo-Jack I, Dobre IA, Tait S, Schumacher L, Fintelmann FJ et al (2022) Management of lung cancer in the patient with interstitial lung disease. Oncologist 25 novembre 28(1):12–22
Zanini U, Faverio P, Bonfanti V, Falzone M, Cortinovis D, Arcangeli S et al (2024) The Liaisons dangereuses between lung cancer and interstitial lung diseases: A focus on acute exacerbation. J Clin Med gennaio 13(23):7085
Dutkowska AE, Antczak A (2016) Comorbidities in lung cancer. Adv Respiratory Med maggio 84(3):186–192
MacMahon H, Naidich DP, Goo JM, Lee KS, Leung ANC, Mayo JR et al (2017) Guidelines for management of incidental pulmonary nodules detected on CT images: From the fleischner society 2017. Radiol luglio 284(1):228–243
Farjah F, Monsell SE, Smith-Bindman R, Gould MK, Banegas MP, Ramaprasan A et al (2022) Fleischner society guideline recommendations for incidentally detected pulmonary nodules and the probability of lung cancer. J Am Coll Radiol novembre 19(11):1226–1235
Catelli C, Guerrini S, D’Alessandro M, Cameli P, Fabiano A, Torrigiani G et al (2024) Sarcoid nodule or lung cancer? A high-resolution computed tomography-based retrospective study of pulmonary nodules in patients with sarcoidosis. Diagnostics (Basel) 14(21):2389
Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ et al (2018) Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med settembre 198(5):e44–68
Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL et al (2019) Standardization of spirometry 2019 update. An official American thoracic society and european respiratory society technical statement. Am J Respir Crit Care Med 200(8):e70–88
Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH et al (2012) Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J dicembre 40(6):1324–1343
Matsuguma H, Mori K, Nakahara R, Suzuki H, Kasai T, Kamiyama Y et al (2013) Characteristics of subsolid pulmonary nodules showing growth during follow-up with CT scanning. Chest 1 febbraio 143(2):436–443
Henschke CI, Yankelevitz DF, Mirtcheva R, McGuinness G, McCauley D, Miettinen OS et al (2002) CT screening for lung cancer: Frequency and significance of part-solid and nonsolid nodules. AJR Am J Roentgenol maggio 178(5):1053–1057
Ost D, Fein AM, Feinsilver SH (2003) The solitary pulmonary nodule. New Engl J Med 19 giugno 348(25):2535–2542
Gould MK, Donington J, Lynch WR, Mazzone PJ, Midthun DE, Naidich DP et al (2013) Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest maggio 143(5 Suppl):e93S–e120S
Park J, Kim DS, Shim TS, Lim CM, Koh Y, Lee SD et al (2001) Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respiratory J 1 giugno 17(6):1216–1219
Hubbard R, Venn A, Lewis S, Britton J (2000) Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med gennaio 161(1):5–8
Shao W, Huang J, Feng H, Sun H, Ren Y, Wang X et al (2020) Impact of interstitial lung disease on postoperative morbidity and 90-day mortality after pulmonary resection. Translational Cancer Res [Internet] febbraio [citato 27 novembre 2025] https://tcr.amegroups.org/article/view/36081
Khan KA, Kennedy MP, Moore E, Crush L, Prendeville S, Maher MM et al (2015) Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. Lung febbraio 193(1):71–77
Mondoni M, Varone F, Luppi F, Cameli P, Cerri S, Puci MV et al (2025) Effectiveness of nintedanib in progressive pulmonary fibrosis assessed by progression criteria: An Italian, observational, multicenter study. Lung 8 luglio 203(1):77
Cocconcelli E, Bernardinello N, Cameli P, Di Liberti R, Alhamad EH, Gregori D et al (2025) Prevalence and predictors of response to antifibrotics in long-term survivors with idiopathic pulmonary fibrosis. Lung 203(1):35
Cefalo J, Varone F, Luppi F, Cameli P, Cerri S, Puci MV et al Impact of dosing on functional and clinical outcomes of patients with progressive pulmonary fibrosis treated with Nintedanib: data from a real-world, multicentric, Italian study. Archivos de Bronconeumología [Internet]. 20 novembre 2025 [citato 27 novembre 2025]; Disponibile su: https://www.sciencedirect.com/science/article/pii/S0300289625004120
Vancheri C (2015) Idiopathic pulmonary fibrosis and cancer: do they really look similar? BMC Med 13(1):220
Ryu JH, Colby TV, Hartman TE, Vassallo R (2001) Smoking-related interstitial lung diseases: a concise review. Eur Respiratory J 1 gennaio 17(1):122–132
Althobiani MA, Russell AM, Jacob J, Ranjan Y, Folarin AA, Hurst JR et al (2024) Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment. Front Med (Lausanne) 11:1296890
Article PubMed PubMed Central Google Scholar
Pianigiani T, Dilroba A, Gambini C, Hernandez-Gonzalez F, d’Alessandro M, Bergantini L et al (2025) Beyond Inflammation: Alarmins as Critical Drivers of Pulmonary Fibrosis. ERJ Open Research [Internet]. 18 settembre 2025 [citato 30 ottobre 2025]; Disponibile su: https://publications.ersnet.org/content/erjor/early//09/11/23120541.00747-2025
Wuyts WA, Agostini C, Antoniou KM, Bouros D, Chambers RC, Cottin V et al (2013) The pathogenesis of pulmonary fibrosis: A moving target. Eur Respir J maggio 41(5):1207–1218
Cerro Chiang G, Parimon T (2023) Understanding interstitial lung diseases associated with connective tissue disease (CTD-ILD): Genetics, cellular pathophysiology, and biologic drivers. Int J Mol Sci 26 gennaio 24(3):2405
Comments (0)